Allogene Therapeutics ALLO Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Allogene Therapeutics (ALLO) reported comprehensive income (loss), net of tax, attributable to parent of -$43.06M in Q1 2026.
- How has Allogene Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Allogene Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 27.8% year-over-year, from -$59.6M to -$43.06M.
- What is the long-term trend for Allogene Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Allogene Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 0.8% compound annual growth rate (CAGR), from -$184.89M to -$190.53M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric measures the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on investments. It provides a more holistic view of a company's financial performance by capturing fluctuations in value that are not reflected in the traditional income statement. This figure is essential for assessing the overall impact of market conditions and accounting adjustments on the company's total equity base.